BioSpace News Archive

Aker BioMarine, the global biotech innovator and world-leading supplier of krill, announces the appointment of biotechnology and pharmaceutical executive Douglas C. Hicks to the position of Senior Vice President – Business Development and Strategy, to lead Aker BioMarine’s entry into the pharmaceutical segment.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company’s business strategy and development-stage programs at two upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference 2021 . A fireside chat presentation is scheduled for Thursday, June 3, 2021, at 9:30 a.m.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Company’s proprietary Versamune® T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta

- Tuesday, June 1 st – 3:30 p.m. ET - Nuvo Pharmaceuticals ® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, has been invited to present at the Summer Solstice

Deal allows global cardiac device manufacturer to enhance its offerings in the U.S. with Implicity’s cloud-based and AI-driven universal cardiac remote monitoring platform to provide high-value services to healthcare providers

- Syndicate includes existing investors Vensana Capital and Amgen Ventures joined by new healthcare investor - Amgen Vice President of Research Philip Tagari, joins company’s board of directors

Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Sesen Bio President and CEO Dr. Thomas Cannell will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021.

Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA ® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit --